(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 July 2019 (18.07.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/140216 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:
PCT/US2019/013227

(22) International Filing Date:
11 January 2019 (11.01.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/617,157 12 January 2018 (12.01.2018) US

(71) Applicant: **AMGEN INC.** [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(72) Inventors: **AGRAWAL, Neeraj Jagdish**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **CHEN, Irwin**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **CHONG, Su**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **FUCHSLOCHER, Bryna**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **GRAHAM, Kevin**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **HAMBURGER, Agnes Eva**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **MICHAELS, Mark Leo**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **MOHR, Christopher**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **PIPER, Derek E.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WALKER, Kenneth William**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **WANG, Zhulun**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). **XU, Cen**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(74) Agent: **PURCELL, Angela L.**; c/o Amgen Inc., One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: PAC1 ANTIBODIES AND USES THEREOF



FIG. 1A

(57) Abstract: The present invention relates to neutralizing antibodies of the human pituitary adenylate cyclase activating polypeptide type I receptor (PAC1) and pharmaceutical compositions comprising such antibodies. Methods of treating or preventing headache conditions, such as migraine and cluster headache, using the neutralizing antibodies are also described.

WO 2019/140216 A1

[Continued on next page]

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*